site search by freefind

Home

Contact Us

Our Mission

Our Accomplishments

How You Can Help

In Memory of

Q&As

News

Positions

Other Websites

| How we spend donated money | Our thanks for your donations |
| Help fund a specific upcoming study | Directors, Officers, Advisors |


Clinical & Scientific Achievements

The single most important accomplishment of FRF-related research is  a clinical achievement: We developed and refined the form of treatment termed "metabolic rehabilitation." Some 75% to 85% of patients diagnosed as having fibromyalgia who undergo metabolic rehabilitation completely and lastingly recover. By "recover" we mean the patients no longer meet the American College of Rheumatology criteria for fibromyalgia. The patients are symptom free and fully functional at long-term follow-up.

Publications

Our work has been cited or described in
at least twenty-three books. These books include:

1. Ridha Arem, MD: The Thyroid Solution. New York, Ballantine Books, 1999.

2. Ken Blanchard, MD and Marietta Abrams Brill. What Your Doctor May Not Tell You About Hypothyroidism: A Simple Plan for Extraordinary Results. Warner Books, 2004.

3. David Brownstein, MD. Overcoming Thyroid Disorders. Medical Alternatives Press, Inc. 2002.

4. Leon Chaitow, ND, DO: Fibromyalgia Syndrome: A Practitioner's Guide to Treatment. London, Churchill Livingston, 2000.

5. Leon Chaitow, ND, DO: Fibromyalgia and Muscle Pain, 2nd edition. London, Thorsons, 1998.

6. Barry Durrant-Peatfield, MB, S, LRCP, MRCS: The Great Thyroid Scandal and How to Survive It. London, Barons Down Publishing, 2002.

7. Jonathan Forester, MD. Conquering Chronic Fatigue: Answers to America's Most Misunderstood Epidemic. Ventura, Regal Books, 2003.

8. C.C. Goodman, PT, W.G. Boissonnault, and K. Fuller: Pathology: Implications for the Physical Therapist, 2nd ed., Philadelphia, Harcourt Health Sciences, 2002.

9. Gina Honeyman-Lowe, DC and John C. Lowe, MA, DC: Your Guide to Metabolic Health. McDowell Health-Science Books, Boulder, 2002.

10. Stephen Langer, MD and James Scheer: Solved: The Riddle of Illness, 3rd edition. New Canaan, Keats Publishing, Inc., 2000.

11. Life Extension Foundation. Disease Prevention and Treatment, 4th edition. Life Extension Media, 2003.

12. John C. Lowe, MA, DC: The Metabolic Treatment of Fibromyalgia. Boulder, McDowell Publishing Company, 2000.

13. Siegfried Mense, Dr Med and David G. Simons, MD: Muscle Pain: Understanding Its Nature, Diagnosis, and Treatment. Philadelphia, Lippincott Williams & Wilkins, 2001.

14. J. Pizzorno, ND and M. Murray, ND.: A Textbook of Natural Medicine, 3rd ed., 2006.

15. Mary Shomon: Living Well With Hypothyroidism. New York, Avon Books, 2000.

16. Mary Shomon: Living Well with Autoimmune Disease. New York, HarperCollins, 2002.

17. Mary Shomon: Living Well with Chronic Fatigue Syndrome & Fibromyalgia. New York, HarperCollins, 2004.

18. Mary Shomon: Living Well with Graves' Disease and Hyperthyroidism. New York, HarperCollins, 2005.

19. David G. Simons, MD, Janet G. Travell, MD, and Lois S. Simons, PT: Travell & Simons' Myofascial Pain and Dysfunction: The Trigger Point Manual, vol.1, 2nd. edition. Philadelphia, Lippincott, Williams & Wilkins, 1998.

20. Devin Starlanyl, MD: The Fibromyalgia Advocate. Oakland, New Harbinger Publications, Inc., 1998.

21. Devin Starlanyl, MD and Mary Ellen Copeland, MA: Fibromyalgia & Chronic Myofascial Pain Syndrome, 2nd edition. Oakland, New Harbinger Publications, Inc., 2001.

22. Jacob Teitelbaum, MD: From Fatigue to Fantastic, 2nd edition. New York, Avery, 2001.

23. Janie A. Bowthorpe: Stop the Thyroid Madness. Moab UT, Laughing Grape Publishing, 2008.

The following twenty-five journal papers have 
resulted from the research activities of FRF:

1. Lowe, J.C., et al.: Improvement in euthyroid fibromyalgia patients treated with T3 (tri-iodothyronine). J. Myofascial Ther., 1(2):16-29, 1994.

2. Lowe, J.C.: T3-induced recovery from fibromyalgia by a hypothyroid patient resistant to T3 and desiccated thyroid. J. Myofascial Ther., 1(4):21-30, 1995.

3. Lowe, J.C., Garrison, R.L., Reichman, A.J., Yellin, J., Thompson, M., and Kaufman, D.: Effectiveness and safety of T3 (triiodothyronine) therapy for euthyroid fibromyalgia: a double-blind placebo-controlled response-driven crossover study. Clin. Bull. Myofascial Ther., 2:(2/3):31-58, 1997.

4. Honeyman, G.: Metabolic therapy for hypothyroid and euthyroid fibromyalgia: two case reports. Clin. Bull. Myofascial Ther., 2(4):19-49, 1997.

5. Lowe, J.C., Reichman, A.J., and Yellin, J.: The process of change during T3 treatment for euthyroid fibromyalgia: a double-blind placebo-controlled crossover study. Clin. Bull. Myofascial Ther., 2(2/3): 91-124, 1997.

6. Lowe, J.C.: Thyroid status of 38 fibromyalgia patients: implications for the etiology of fibromyalgia. Clin. Bull. Myofascial Ther., 2(1):47-64, 1997.

7. Lowe, J.C., Garrison, R.L., Reichman, A.J., and Yellin, J.: Triiodothyronine (T3) treatment of euthyroid fibromyalgia: a small-N replication of a double-blind placebo-controlled crossover study (abstract). Clin. Bull. Myofascial Ther., 3(14):23-24, 1997.


8. Lowe, J.C.: Results of an open trial of T3 therapy with 77 euthyroid female fibromyalgia patients. Clin. Bull. Myofascial Ther., 2 (1):35-37, 1997.


9. Lowe, J.C., Cullum, M., Graff, L., and Yellin, J.: Mutations in the c-erbAß1 gene: do they underlie euthyroid fibromyalgia? Medical Hypotheses, 48:125-135, 1997.

10. Yellin, J.:  Why is substance P high in fibromyalgia? Clin.Bull. Myofascial Ther., 2(2/3):23-30, 1997.

11. Lowe, J.C., Reichman, A., and Yellin, J.: A case-control study of metabolic therapy for fibromyalgia: long-term (1-to- 5 year) follow-up comparison of treated and untreated patients (abstract). Clin. Bull. Myofascial Ther., 3(1):23-24, 1998.

12. Lowe, J.C., Reichman, A.J., et al.: Thyroid status of fibromyalgia patients. Clin. Bull. Myofascial Ther., 3 (1):47-53, 1998.

13. Lowe, J.C. et al.: Facilitating the decrease in fibromyalgic pain during metabolic rehabilitation: an essential role for soft tissue therapies. J. Bodywork Movem. Ther., 2(4):208-217, 1998.

14. Lowe, J.C. et al.: Thyroid dysfunction and fibromyalgia. In Fibromyalgia Syndrome: A Practitioner’s Guide to Treatment, edited by Leon Chaitow, N.D., D.O., Edinburgh, Churchill Livingston, 1999.

15. Lowe, J.C.: The Metabolic Treatment of Fibromyalgia. Boulder, McDowell Publishing Co., 2000.

16. Lowe, J.C. and Honeyman-Lowe, G.: Ultrasound treatment for trigger points: differences in technique for myofascial pain syndrome and fibromyalgia patients. Lyon Méditerranée Médical: Médecine du Sud-Est. 2:12-15, 1999.

17. Lowe, J.C. and Honeyman-Lowe, G.: Fibromyalgia and thyroid disease. Paper presented in Grenoble, France, May 6 (conference of the French Fibromyalgia Association of Région Rhône-Alpes) and discussed in Toulon, France on May 11 (at the Centre Hospitalier Intercommunal), 2000.

18. Honeyman, G.: Ultrasound treatment of the fibromyalgia patient. Paper presented at the French Fibromyalgia Association of Région Rhône-Alpes, Grenoble, France, May 6, 2000.

19. Lowe, J.: Thyroid disease and fibromyalgia syndrome. Lyon Méditerranée Médical: Médecine du Sud-Est., 36(1):15-17, 2000.

20. Lowe, J.C. and Honeyman-Lowe, G.: Fibromyalgia: a debilitating syndrome. Chiro. Prod., Aug. 2000, pp. 48-52.

21. Honeyman, G.: Ultrasound treatment of the fibromyalgia patient. Lyon Méditerranée Médical: Médecine du Sud-Est., 36(1):3O-31, 2000.

22. Eisinger, J., Starlanyl, D., Blotman, F., Bueno, L., Houvenagel, E., Juvin, R., Kaminsky, P., Lawson, K., Le Loët, X., Lowe, J.C., Manesse, P., Mechtouf, K., Memran, N., Muller, W., Nicollet, M., Perragut, J.C., Plantamura, A., Poinsignon, J.P., Reig, E., Ruiz Lopez, R., Schmitt, K.L., Sichère, P., Teitelbaum, J., Trèves, R., and Zakarian, H.: Protocole d’informations anonyme sur les fibromyalgiques. Lyon Méditerranée Médical: Médecine du Sud-Est., 36:9-11, 2000.

23. Lowe, J.C., Yellin, J., and Honeyman, G.: Female fibromyalgia patients: lower resting metabolic rates than matched healthy controls. Medical Science Monitor, 12(7):CR1-CR8, 2006.

24. Lowe, J.C., Honeyman, G., and Yellin, J.: Lower resting metabolic rate and basal body temperature of fibromyalgia patients compared to matched healthy controls. Thyroid Science, 1:T1-T24, 2006.

25. Lowe, J.C. and Yellin, J.G.: Inadequate thyroid hormone regulation as the main mechanism of fibromyalgia: a review of the evidence. Thyroid Science, 3(6):R1-14, 2008.

 

For questions about the Fibromyalgia Research Foundation
and its on-going research, please write to us at 
tammy@FibromyalgiaResearch.org

michele@FibromyalgiaResearch.org

 

Please help by donating to the Foundation's ongoing research.

  

"In 1996 and 1997, our FRF research team conducted and published three double-blinding placebo-controlled crossover studies. In the studies, we tested  the effectiveness of T3, the most metabolically-active thyroid hormone, for fibromyalgia patients. In the three studies, we found that we significantly decreased and increased patients' pain distribution. In T3 phases of the studies, their pain distribution decreased; in placebo phases, their pain increased again. The effect of T3 and placebos on their pain was akin to decreasing and increasing  flow of very cold water by turning the faucet handle one way and then decreasing it by turning in the other way."

Dr. John C. Lowe



The line graph below is from one of FRF's three double-blind studies published in 1997. The trend line in the graph shows a study patient's changing pain distribution during four phases of the study. The red line and data points represent her pain distribution (the percentage of her body in pain) during the baseline phase (far left in the graph), and during two placebo phased (to the right in the graph). The blue line and data points represent the patient's pain distribution during the two T3 phases of the study.

The FRF research team found that during the two T3 phases, the patient's pain distribution significantly decreased; during the two placebo phases, her pain precipitously increased. As with the most other patients in the three 1996-1997 studies, FRF researchers decreased and increased the pain distribution by switching patients from T3 to placebos.

References to the three
1997 study reports:

Lowe, J.C., Garrison, R.L., Reichman, A.J., Yellin, J., Thompson, M., and Kaufman, D.: Effectiveness and safety of T3 (triiodothyronine) therapy for euthyroid fibromyalgia: a double-blind placebo-controlled response-driven crossover study. Clin. Bull. Myofascial Ther., 2:(2/3):31-58, 1997.

Lowe, J.C., Reichman, A.J., and Yellin, J.: The process of change during T3 treatment for euthyroid fibromyalgia: a double-blind placebo-controlled crossover study. Clin. Bull. Myofascial Ther., 2(2/3): 91-124, 1997.

Lowe, J.C., Garrison, R.L., Reichman, A.J., and Yellin, J.: Triiodothyronine (T3) treatment of euthyroid fibromyalgia: a small-N replication of a double-blind placebo-controlled crossover study (abstract). Clin. Bull. Myofascial Ther., 3(14):23-24, 1997.